Jonas Subelack
Thumbnail Image
Last Name
Subelack
First name
Jonas
Email
jonas.subelack@unisg.ch
ORCID
LinkedIn

Filters
1
1
Reset filters

Settings
Now showing 1 - 1 of 1
No Thumbnail Available
Publication

Breast cancer patients enrolled in the Swiss mammography screening program “donna” demonstrate prolonged survival

2024 , David Kuklinski , Marcel Blum , Jonas Subelack , Alexander Geissler , Alena Eichenberger , Rudolf Morant , Springer

Study goal We compared the survival rates of women with breast cancer (BC) detected within versus outside the mammography screening program (MSP) “donna”. Methods We merged data from the MSP with the data from corresponding cancer registries to categorize BC cases as within MSP (screen-detected and interval carcinomas) and outside the MSP. We analyzed the tumor stage distribution, tumor characteristics and the survival of the women. We further estimated hazard ratios using Cox-regressions to account for different characteristics between groups and corrected the survival rates for lead-time bias. Results We identified 1057 invasive (ICD-10: C50) and in-situ (D05) BC cases within the MSP and 1501 outside the MSP between 2010 and 2019 in the Swiss cantons of St. Gallen and Grisons. BC within the MSP had a higher share of stage I carcinoma (46.5% vs. 33.0%; < 0.01), a smaller (mean) tumor size (19.1 mm vs. 24.9 mm, < 0.01), and fewer recurrences and metastases in the follow-up period (6.7% vs. 15.6%,  < 0.01). The 10-year survival rates were 91.4% for women within and 72.1% for women outside the MSP (< 0.05). Survival difference persisted but decreased when women within the same tumor stage were compared. Lead-time corrected hazard ratios for the MSP accounted for age, tumor size and Ki-67 proliferation index were 0.550 (95% CI 0.389, 0.778; for overall survival and 0.469 (95% CI 0.294, 0.749; < 0.01) for BC related survival. Conclusion Women participating in the “donna” MSP had a significantly higher overall and BC related survival rate than women outside the program. Detection of BC at an earlier tumor stage only partially explains the observed differences.

View